A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 4, 2012, Pages 531-537

  Teramoto, Koji ^a   Asada, Yoshikuni ^b   Ozaki, Yoshitomo ^a   Suzumura, Yuji ^c   Nakano, Yasutaka ^a   Sawai, Satoru ^a   Tezuka, Noriaki ^a   Inoue, Shuhei ^d   Fujino, Shozo ^a,e  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b NAGAHAMA RED CROSS HOSPITAL   (Japan)

^c Ijinkai Takeda General Hospital   (Japan)

^d National Hospital Organization   (Japan)

^e TEIKYO UNIVERSITY MIZONOKUCHI HOSPITAL   (Japan)

Author keywords

Chemotherapy; Docetaxel; Nedaplatin; NSCLC; Squamous cell carcinoma

Indexed keywords

DOCETAXEL; NEDAPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CONTROL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TAXOIDS;

EID: 84867574423     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1941-8     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M (2004) Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859
3. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R, CISCA (CISplatin versus CArboplatin) Meta-analysis Group (2007) Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847-857
4. Jiang J, Liang X, Zhou X, Huang R, Chu Z (2007) A metaanalysis of randomized controlled trials comparing carboplatinbased to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348-358
5. Shiratori O, Kanai H, Uchida N (1985) Antitumor activity of 254-S, a platinum complex, in rodents. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, Tokyo, pp 635-636
6. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolate-O, O0) diammineplatium (II), a novel platinum complex, in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 26:393-396
7. Furuse K, Fukuoka M, Kurita Y, Ariyoshi Y, Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Gan To Kagaku Ryoho 19:879-884
8. Furuse K, Fukuoka M, Asamoto H, Niitani H, Kiura I, Sakuma A, Yamaguchi Y (1992) A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC). Gan To Kagaku Ryoho 19:1019-1026
9. Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J (1998) Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953
10. Le Chevalier T, Monnier A, Douillard JY, Ruffie P, Sun XS, Belli L, Ibrahim N, Bougon N, Bérille J (1998) Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small-cell lung cancer. Eur J Cancer 34:2032-2036
11. Georgoulias V, Androulakis N, Dimopoulos AM, Kourousis C, Kakolyris S, Papadakis E, Apostolopoulou F, Papadimitriou C, Vossos A, Agelidou M, Heras P, Tzannes S, Vlachonicolis J, Mavromanolakis E, Hatzidaki D (1998) First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 9:331-334
12. Fujino S (2003) Combination chemotherapy with nedaplatin and docetaxel as a treatment of squamous cell lung cancers. Jpn J Lung Cancer 43:900-905
13. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumor. European Organization for Research and treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
15. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall- cell-lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210-3218
16. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G, European Organization for Research and Treatment of Cancer Lung Cancer Group (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21: 3909-3917
17. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M, Italian Lung Cancer Project (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291
18. Shirai T, Hirose T, Noda M, Ando K, Ishida H, Hosaka T, Ozawa T, Okuda K, Ohnishi T, Ohmori T, Horichi N, Adachi M (2006) Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer 52: 181-187
19. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage NSCLC. J Clin Oncol 26:3543-3551
20. Oshita F, Honda T, Murakami S, Kondo T, Saito H, Noda K, Yamada K (2011) Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials. J Thorac Oncol 6:128-131
21. Oshita F, Ohe M, Honda T, Murakami S, Kondo T, Saito H, Noda K, Yamashita K, Nakayama Y, Yamada K (2010) Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. Br J Cancer 103:1325-1330
22. Rudd RM, Gpwer NH, Spiro SG, Eisen TG, Harper PG, Littler JA, Hatton M, Johnson PW, Martin WM, Rankin EM, James LE, Gregory WM, Qian W, Lee SM (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London lung cancer group. J Clin Oncol 23:142-153
23. Zatloukal P, Petruzelka L, Zemanova M, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M (2003) Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIB and IV non-small-cell lung cancer: a phase III randomized trial. Lung Cancer 41:321-331